Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Efficacy and safety of Lenzumestrocel (Neuronata-R (R) inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trialopen access

Authors
Nam, Jae-YongLee, Tae YongKim, KwijooChun, SehwanKim, Min SungShin, Jin-HongSung, Jung-JoonKim, Byoung JoonKim, Byung-JoOh, Ki-WookKim, Kyung SukKim, Seung Hyun
Issue Date
18-5월-2022
Publisher
BMC
Keywords
Lenzumestrocel; Amyotrophic lateral sclerosis; Bone marrow-derived mesenchymal stem cell; Phase III
Citation
TRIALS, v.23, no.1
Indexed
SCIE
SCOPUS
Journal Title
TRIALS
Volume
23
Number
1
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/142253
DOI
10.1186/s13063-022-06327-4
ISSN
1745-6215
Abstract
Background: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clinical trial (ALSUMMIT) protocol was developed to evaluate the long-term efficacy and safety of the combined protocol of single-cycle intrathecal therapy and three additional booster injections of BM-MSC (Lenzumestrocel) treatment in patients with ALS. Methods: ALSUMMIT is a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial for ALS. The 115 subjects will be randomized (1:2:2) into three groups: (1) study Group 1 (single-cycle, two repeated injections with 26-day interval), (2) study Group 2 (single-cycle + three additional booster injections at 4, 7, and 10 months), and (3) the control group. Participants who have an intermediate rate of disease progression will be included in this trial to reduce clinical heterogeneity. The primary endpoint will be evaluated by combined assessment of function and survival (CAFS), also known as joint rank scores (JRS), at 6 months (study Group 1 vs. control) and 12 months (study Group 2 vs. control) after the first Lenzumestrocel or placebo administration. Safety assessment will be performed throughout the study period. Additionally, after the 56-week main study, a long-term follow-up observational study will be conducted to evaluate the long-term efficacy and safety up to 36 months. Discussion: Lenzumestrocel is the orphan cell therapy product for ALS conditionally approved by the South Korea Ministry of Food and Drug Safety (MFDS). This ALSUMMIT protocol was developed for the adoption of enrichment enrolment, add-on design, and consideration of ethical issues for the placebo group.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Byung Jo photo

Kim, Byung Jo
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE